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adjuvanted Q-antigen. At days 0, 21 and 42, sera were
tested for hemagglutination-inhibiting (HI) antibody against
A/Indonesia/5/2005 and A/Vietnam/1194/2004 (Clade 1).
Solicited local and general symptoms, unsolicited adverse
events (AEs) and serious adverse events (SAEs) were
recorded. (110028/NCT00510874).
Although injection site pain was more frequent in the AS-
adjuvanted vaccine groups, redness and swelling occurred
in <5% of subjects. General symptoms (day 0—6) were more
frequent in the AS vaccine groups but fever was uncommon
(≤2%). All AEs decreased after dose 2. Clinical laboratory
values and unsolicited AEs raised no safety concerns. No
vaccine-related SAEs occurred.
After dose 1, A/Indonesia seroconversion rates (SCR)
reached 42.1%—45.7% in the AS vaccine groups (con-
trol:6.7%). After dose 2, SCR and the percent of subjects
with HI titers ≥40 were 96.4%—97.2% in the AS vaccine
groups (control:17.3%). Homologous HI GMT was enhanced
≥44-fold in the pooled AS vaccine group. After 2 doses, SCR
to Clade 1A/Vietnam/1194/04 was 56.4%—62.1% for the AS
vaccine groups.
At an antigen-sparing dose, the AS-adjuvanted
A/Indonesia/05/2005 vaccines were markedly immunogenic
against the vaccine strain and a Clade 1 strain. Reacto-
genicity was increased but acceptable, and no other safety
concerns were identiﬁed.
doi:10.1016/j.ijid.2008.05.365
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Background: The lyophilized formulation of an oral, live
attenuated human rotavirus (RV) vaccine RIX4414 (Rotarix, a
trademark from GlaxoSmithKline) given concomitantly with
routine vaccines, has been shown to be highly immunogenic.
A phase II, randomised, double-blind, placebo-controlled
study (105722/NCT00345956) was conducted in Vietnam to
assess the immunogenicity, reactogenicity and safety of two
doses of RIX4414 oral suspension(liquid formulation) co-
administered in two different schedules with routine EPI
vaccines.
Methods: Healthy 6—10 week old infants(N = 375) were
enrolled and randomized into three groups to receive either
two doses of RIX4414 oral suspension (RIX4414-liq) and
one placebo(Pl) dose, according to a 0,1 month (RIX4414-
RIX4414-Pl group) or a 0,2 month (RIX4414-Pl-RIX4414
group) schedule, or 3 placebo doses(placebo group). Rou-
tine EPI vaccines were administered concomitantly. Serum
anti-rotavirus IgA concentrations (ELISA,cut-off ≥20U/mL)
were determined at pre-Dose1 and 1 month post-Dose2 of
RIX4414-liq. The anti-rotavirus IgA seroconversion(SC) rates
and corresponding Geometric Mean Concentrations(GMCs)
were calculated. Solicited symptoms were collected 8 days
post-each dose, safety data were collected throughout the
study.
Results: At 1 month post-Dose2 of RIX4414-liq, the
anti-rotavirus IgA SC rate was 63.3%(95%CI:54.3;71.6)
in the RIX4414-RIX4414-Pl group(n = 128) and
81.5%(95%CI:73.4;88.0) in the RIX4414-Pl-RIX4414
group(n = 119). The SC rate observed in the placebo group
at the same time points was 7.8%(95%CI:2.6;17.3)(n = 64)
and 15.4%(95%CI:7.6;26.5)(n = 65). Corresponding anti-
rotavirus IgA GMCs for seropositive infants were
253.8U/mL(95%CI:184.8;348.7) in the RIX4414-RIX4414-Pl
group and 338.0U/mL(95%CI:248.2;460.4) in the RIX4414-
Pl-RIX4414 group. There was no evidence of difference
between the RIX4414-liq groups and the placebo group for
serious adverse events, and for reported solicited events.
Conclusion: This study demonstrates that two doses of
RIX4414 (RotarixTM) oral suspension(liquid formulation) co-
administered with routine EPI vaccines in two different
schedules elicit a high immunogenicity response in Viet-
namese children. Seroconversion rates in this setting are in
line with seroconversion rates observed in a large phaseIII
Latin-America study where high efﬁcacy (85%) was observed
against severe RVGE.
doi:10.1016/j.ijid.2008.05.366
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Background: RIX4414(Rotarix, a trademark of Glax-
oSmithKline), an oral live attenuated human rotavirus
(RV) vaccine has previously been shown to be highly
effective against RV gastroenteritis(GE). The efﬁcacy
evaluation of RIX4414 administered concomitantly with
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routine EPI vaccinations including Oral Polio Vaccine(OPV)
to healthy infants in a phase III, double-blind, ran-
domized, placebo-controlled and multi-center study
(444563/024/NCT00139347) conducted in six countries
in Latin-America is presented.Methods: Healthy infants
aged 6-12 weeks were enrolled to receive two doses of
RIX4414(N = 4376) or placebo(N = 2192) according to a 0,1—2
month schedule, administered concomitantly with Dose 1
and Dose 2 of routine pediatric vaccines including OPV, given
respecting the national immunisation guidelines.Vaccine
efﬁcacy(VE) was calculated from two weeks post-Dose2
until one year of age. Severe GE was deﬁned as an episode
of diarrhea requiring hospitalization and/or re-hydration
therapy in a medical facility. Diarrhoeal samples were ana-
lyzed for RV by ELISA and typed by RT-PCR based method.
Safety data were collected throughout the study.
Results: During the efﬁcacy follow-up period (mean
duration of 7.4 months) RIX4414 has offered 81.6%
(95%CI:54.4;93.5) protection against severe RVGE and 88.3%
(95%CI:64.0;97.1) against hospitalization due to RVGE.
For severe RVGE, VE against wild-type G1 was 100%
(95%CI:<0;100) and 80.6% (95%CI:51.4;93.2) against pooled
non-G1 RV types (G2,G9). No clinically meaningful differ-
ence between RIX4414 group and the placebo group for
serious adverse events were reported.
Conclusion: Two doses of RIX4414(RotarixTM)offer high
protection against severe RVGE and related hospitaliza-
tions when co-administered with speciﬁc childhood vaccines
including OPV. These results show that co-administration
with OPV does not impact the efﬁcacy of RotarixTM and are
in line with the high efﬁcacy against severe RVGE of 85%
demonstrated in a large Phase III Latin America study with
staggered co-administration of OPV. This ﬁnding is of signiﬁ-
cance for the implementation of RV vaccination programmes
in many countries where OPV is still routinely administered.
doi:10.1016/j.ijid.2008.05.367
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Background: The lyophilized formulation of Glaxo-
SmithKline’s oral, live attenuated human rotavirus vaccine
RIX4414(RotarixTM) has shown to be immunogenic in vari-
ous phase III trials in Europe and Latin America. A phase III,
open-label, randomized, study(107077/NCT00363545) was
conducted in Panama to assess the immunogenicity of two
doses of RIX4414 oral suspension (liquid formulation) to
that of the lyophilised formulation with routine vaccinations
given concomitantly.
Methods: Healthy infants, 6—12 weeks old (N = 1274)
were enrolled to receive two doses of RIX4414 oral
suspension(RIX4414-liq) or RIX4414 lyophilized(RIX4414-lyo)
according to a 0,2 month schedule. Routine vaccina-
tions (oral poliovirus vaccines(OPV), DTPw-HBV/Hib) were
administered concurrently following local EPI schedule.
Anti-rotavirus IgA antibody concentrations were assessed at
pre-vaccination and 1 to 2 months post-Dose 2 (ELISA, cut-
off ≥20U/mL). The anti-rotavirus IgA seroconversion rates
and corresponding Geometric Mean Concentrations(GMCs)
were calculated. Solicited symptoms (fever, diarrhoea, irri-
tability, cough/runny nose, loss of appetite, vomiting) were
collected for 15-days after each dose, unsolicited symp-
toms 31-days after each dose. Safety data were collected
throughout the study.
Results: The two RIX4414-liq and RIX4414-lyo groups
had a similar demographic proﬁle. Anti-rotavirus IgA sero-
conversion rates at 1 to 2 months post-Dose2 was 80.8%
(95%CI: 76.9%;84.4%) in the RIX4414-liq group(n = 449)
and was 73.5%(95%CI:69.1%;77.6%) in the RIX4414-lyo
group(n = 434). GMCs calculated in seropositive infants was
287.8U/mL (95%CI:250.2;331.2) in the RIX4414-liq group
and 266.6U/mL (95%CI:228.6;310.8) in the RIX4414-lyo
group. The reactogenicity proﬁle of the RIX4414-liq group
was similar to the RIX4414-lyo group. No vaccination related
serious adverse events.
Conclusion: This study indicates that both formulations
of RIX4414(RotarixTM) elicited a good immune response 1
to 2 months post-Dose2 when co-administered with rou-
tine childhood vaccines. This is of importance in considering
the implementation of rotavirus UMV programmes. The two
formulations were well tolerated with no clinical concerns
raised based on the available safety data.
doi:10.1016/j.ijid.2008.05.368
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Background: Measels cases began to decline in 1990 in
Taiwan just after a 5 year period in which 3 large out-
breaks occurred with one to two thousand cases in the 1980’s
(1985:2219 cases, 97 fatal; 1988: 1386 cases; 1989: 1060
cases, 12 fatal). Since 2003 less than 10 measles cases have
been conﬁrmed annually.
Methods: Specimens including throat swabs, urine, or
sera were collected from 67 patients with serological con-
ﬁrmed infection during the period of 1992—2007. B95a cell
lines were used for virus isolation. After measles virus (MV)
identiﬁcation by immunoﬂuorescence, virus gene targets (N,
nucleoprotein and H, hemagglutinin) were ampliﬁed (RT-
PCR), sequenced and compared to reference sequences.
Results: After diagnostic tests the 67 isolates were
assigned to the following 7 genotypes: A (4), D3 (5), D5 (8),
D9 (2), G2 (3), H1 (42), and H2 (3). The genotype H1 strains
were responsible for cases in 1992 and outbreaks in 1994
and 2002. Most of the genotype H1 cases after 2001 were
derived from China. Epidemiological information showed 16
